SonoThera

SonoThera is a clinical-stage biotechnology company developing ultrasound-mediated, nonviral gene therapy through its proprietary RIPPLE delivery and PORE payload-engineering platforms, which target genetic payloads to specific tissues without viral vectors and allow redosing. Headquartered in South San Francisco, California, the company officially launched in 2022 with a $60.75 million Series A round and is advancing programs toward Duchenne muscular dystrophy, hemophilia A, and X-linked Alport syndrome. It closed an oversubscribed $125 million Series B in early 2026. Investors include Arch Venture Partners, Johnson & Johnson, Vertex Ventures, Illumina Ventures, Eli Lilly, RA Capital, ARK Invest, and Otsuka, and the company holds a research collaboration with Janssen Pharmaceuticals.